NASDAQ:ALXN
Delisted

Alexion Pharmaceuticals Stock Forecast

$182.50
+0 (+0%)
At Close: May 27, 2022
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for Alexion Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Alexion Pharmaceuticals is ALXN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Alexion Pharmaceuticals Stock?
Alexion Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Alexion Pharmaceuticals Stock?
Alexion Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Alexion Pharmaceuticals Stock.

What's the current price of Alexion Pharmaceuticals Stock?
As of the end of day on the 2022-05-27, the price of an Alexion Pharmaceuticals (ALXN) share was $182.50.

What is the 52-week high and low for Alexion Pharmaceuticals Stock?
The 52-week high for Alexion Pharmaceuticals Stock is $187.45 and the 52-week low is $174.72.
Click to get the best stock tips daily for free!

About Alexion Pharmaceuticals

Alexion Pharmaceuticals Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosp... ALXN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT